Though formally founded in 2021, the roots of Precision Cardiovascular trace back nearly two decades. The company’s foundation was shaped by a trio of prominent researchers, including legendary cardiac surgeon Prof. Sir Magdi Yacoub, whose operating room experience underscored a recurring truth: many late-stage heart failure cases could have been prevented with better out-of-hospital monitoring.
Join moderator Amir Soltanianzadeh and Dr. Asif Ali from the American Heart Association as they explore how wearable technology is revolutionizing cardiac care and shaping its future.
Join moderator Henry Peck along with speakers Josh DeFonzo (Mendaera, Inc.) and Andy McGibbon (Vitestro) as they explore how scaling robotics beyond specialized uses can address medical scarcity and rising healthcare costs.
The seeds of Heart Biotech were planted three decades ago at the Magdi Yacoub Institute at Harefield Heart Science Centre, where Sir Magdi embarked on a mission to unlock tissue regeneration. That vision evolved into a singular goal: create a scaffold that could be implanted into the body and instruct it to regrow natural, fully functional cardiac tissue.
Every week, LSI’s Market Intelligence team dives into a different topic shaping the future of medical technology. From disruptive startups to fast-growing device segments, we connect the dots between clinical demand, market dynamics, and innovation pipelines. Here’s what the LSI Market Intelligence team tracked this past month across electrophysiology (EP), transcatheter mitral valve replacement (TMVR), and the U.S. and APAC medtech markets.
The global rise of end-stage kidney disease (ESKD) highlights a longstanding truth: while dialysis is life-saving, it remains a costly, labor-intensive, and outdated solution. In an era marked by aging populations and chronic disease, the urgency to modernize how we manage kidney failure is only growing.
Hy2Care was founded in 2014 by Dr. Sanne Both and Prof. Marcel Karperien at the University of Twente. Both brought firsthand experience of the shortcomings in existing cartilage treatments. Karperien, a leading voice in cartilage biology, partnered with her to translate frustration into innovation.
Join moderator David Hochman (Orchestra BioMed, Inc.) and speaker Chris Eso (Medtronic) as they discuss groundbreaking innovations and strategic partnerships reshaping cardiac pacing, device-based hypertension therapies, and risk-reward sharing models in medtech.
Lisa Earnhardt’s keynote at LSI USA ’25 offered a compelling look at what it takes to lead in today’s medtech landscape. Drawing from her experience scaling startups, taking companies public, and overseeing Abbott’s global medical device business, Lisa shared insights on building transformative technologies and navigating the challenges of growth, innovation, and leadership.
In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni achieve regulatory milestones, present promising interim clinical results, secure new funds, and much more on the road to LSI Asia ‘25 in Singapore (June 10-13).
Under the direction of CTO Maria Kristina Bartolo, Orthonika is reimagining the treatment of irreparable meniscal injuries with its total meniscus replacement (TMR) implant. This novel solution addresses a critical gap in orthopedics, offering new hope to patients suffering from knee pain and impaired mobility. By combining innovative design with expert guidance from leading orthopedic surgeons, Orthonika aims to revolutionize joint preservation and enhance patient quality of life.
In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $81M in new funds, complete a first-in-human trial, appoint new executives, and much more on the road to LSI USA ‘25 in Dana Point, CA (March 17-21).
